News 07.05.19

We need to look for new ways to translate basic research into healthcare

Saman Honarnejad studied biotechnology in Germany and the United States. For several years he has been project manager at Pivot Park Screening Centre (PPSC). PPSC screens candidate drugs through automated processes, enabling very large number of parallel experimentation. Honarnejad is in charge of COILED drug discovery program at PPSC, a joint effort between various academic institutions and biotechnology companies that is stimulating the discovery of new drug candidates. He is an advocate of open innovation, enabling translation of new insights from basic research in industry

Read more
News 02.05.19

The European Lead Factory, Europe’s largest collaborative drug discovery platform, continues its success story

The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (European Screening Centre: unique library for attractive biology) under the European Lead Factory brand.

Read more
News 25.04.19

New at Pivot Park – Cytura Therapeutics

Recently Cytura Therapeutics opened the doors to its laboratory at Pivot Park. Cytura Therapeutics is focused on Developing a new class of drugs targeting genomic instability in cancer. Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC.

Read more
News 23.04.19

Voucher gives rise to collaboration

Synaffix has developed a new technology for targeted anti-cancer therapy. Specifically, Synaffix has improved the therapeutic window of an antibody-drug...

Read more
News 11.04.19

Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen

Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the...

Read more
News 09.04.19

New at Pivot Park – Absano

AbSano develops novel antibodies for innovative diagnostic tools as well as therapeutic purposes. “Our current projects involve the identification and...

Read more
News 08.04.19

BioConnection invests in expansion of its current production capacity with a second production line

BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand...

Read more
News 05.04.19

A cup of coffee with….Lonneke Meijerink (Pivot Park)

Since March Lonneke started working at the Pivot Park Site Organisation as financial accountant. “After studying Business Economics at Tilburg...

Read more
News 01.04.19

Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem's proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with enhanced efficacy and/or safety.

Read more